Safety, tolerability and metabolic effects of once weekly GL0034 (Utreglutide) in individuals with obesity: a multiple ascending dose study

被引：0
|
作者：
Thennati, R. [1 ]
Burade, V. [1 ]
Nagarajan, M. [1 ]
Shahi, P. [1 ]
Nagaraja, R. [1 ]
Agrawal, S. [1 ]
Duvauchelle, T. [2 ]
Garcia-Ocana, A. [3 ]
Rutter, G. [4 ,5 ]
Pratley, R. E. [6 ]
Thorens, B. [7 ]
Vilsboll, T. [8 ,9 ]
机构：
[1] Sun Pharmaceut Ind Ltd, Vadodara, India
[2] Phaster 1, Le Plessis Trevise, France
[3] Arthur Riggs Diabet & Metab Res Inst, Dept Mol & Cellular Endocrinol, Duarte, CA USA
[4] Imperial Coll London, Dept Metab, Digest, Reprod, London, England
[5] Univ Montreal, Crchum, Quebec City, PQ, Canada
[6] AdventHealth, Translat Res Inst Metab & Diabet, Orlando, FL USA
[7] Univ Lausanne, Ctr Integrat Genom, Lausanne, Switzerland
[8] Steno Diabet Ctr Copenhagen, Clin Res, Herlev, Denmark
[9] Univ Copenhagen, Copenhagen, Denmark
来源：
DIABETOLOGIA | 2024年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
751
引用
收藏
页码：S359 / S360
页数：2
相关论文
共 50 条
  • [1] Safety, Tolerability, and Metabolic Effects of Once-Weekly GL0034 (Utreglutide) in Individuals with Obesity-A Multiple Ascending Dose Study
    Thennati, Rajamannar
    Burade, Vinod S.
    Natarajan, Muthukumaran
    Shahi, Pradeep
    Nagaraja, Ravishankara
    Agrawal, Sudeep K.
    Duvauchelle, Thierry
    Garcia-Ocana, Adolfo
    Rutter, Guy A.
    Pratley, Richard E.
    Thorens, Bernard
    Vilsboll, Tina
    DIABETES, 2024, 73
  • [2] Safety and Tolerability of Once-Weekly GL0034 (Utreglutide) in Healthy Individuals-A Multiple Ascending Dose Study
    Thennati, Rajamannar
    Burade, Vinod S.
    Natarajan, Muthukumaran
    Shahi, Pradeep
    Nagaraja, Ravishankara
    Panchal, Satish T.
    Agrawal, Sudeep K.
    Jandrain, Bernard
    Duvauchelle, Thierry
    Garcia-Ocana, Adolfo
    Rutter, Guy A.
    Pratley, Richard E.
    Thorens, Bernard
    Vilsboll, Tina
    DIABETES, 2023, 72
  • [3] Safety and tolerability of multiple ascending doses of once-weekly GL0034 (utreglutide) in healthy individuals
    Burade, V.
    Thennati, R.
    Natarajan, M.
    Shahi, P.
    Nagaraja, R.
    Panchal, S.
    Agrawal, S.
    Jandrain, B.
    Duvauchelle, T.
    Garcia-Ocana, A.
    Rutter, G. A.
    Pratley, R. E.
    Thorens, B.
    Vilsboll, T.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S323 - S323
  • [4] A single ascending dose study of the novel GLP-1 receptor agonist GL0034 (utreglutide) in individuals with obesity without diabetes
    Thennati, R.
    Burade, V.
    Natarajan, M.
    Shahi, P.
    Nagaraja, R.
    Panchal, S.
    Agrawal, S.
    Jandrain, B.
    Duvauchelle, T.
    Garcia-Ocana, A.
    Rutter, G. A.
    Pratley, R. E.
    Thorens, B.
    Vilsboll, T.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S320 - S321
  • [5] A Single Ascending Dose Study of the Novel GLP-1 Receptor Agonist GL0034 (Utreglutide) in Obese Individuals without Diabetes
    Thennati, Rajamannar
    Burade, Vinod S.
    Natarajan, Muthukumaran
    Shahi, Pradeep
    Nagaraja, Ravishankara
    Panchal, Satish T.
    Agrawal, Sudeep K.
    Jandrain, Bernard
    Duvauchelle, Thierry
    Garcia-Ocana, Adolfo
    Rutter, Guy A.
    Pratley, Richard E.
    Thorens, Bernard
    Vilsboll, Tina
    DIABETES, 2023, 72
  • [6] GL0034 (Utreglutide), a long acting, glucagon-like peptide-1 receptor agonist, improves body weight loss, lipid and liver injury markers in individuals with obesity: A phase 1 multiple ascending dose study
    Thennati, Rajamannar
    Burade, Vinod
    Natarajan, Muthukumaran
    Shahi, Pradeep
    Nagaraja, Ravishankara
    Agrawal, Sudeep
    Jandrain, Bernard
    Duvauchelle, Thierry
    Pratley, Richard E.
    Thorens, Bernard
    Vilsboll, Tina
    Loomba, Rohit
    JOURNAL OF HEPATOLOGY, 2024, 80 : S615 - S616
  • [7] A Phase 1 Single Ascending Dose Study of the Novel GLP-1R Agonist GL0034 in Subjects With Obesity
    Thennati, Rajamannar
    Burade, Vinod
    Natarajan, Muthukumar
    Shahi, Pradeep
    Nagaraja, Ravishankara
    Panchal, Satish
    Agrawal, Sudeep
    Jandrain, Bernard
    Duvauchelle, Thierry
    Pratley, Richard
    Thorens, Bernard
    Vilsboll, Tina
    OBESITY, 2023, 31 : 284 - 284
  • [8] Multiple Ascending Dose of the Novel GLP-1RA Utreglutide in Individuals With Obesity-A Phase I Study
    Thennati, Rajamannar
    Burade, Vinod
    Natarajan, Muthukumaran
    Shahi, Pradeep
    Nagaraja, Ravishankara
    Agrawal, Sudeep
    Duvauchelle, Thierry
    Pratley, Richard
    Thorens, Bernard
    Vilsboll, Tina
    OBESITY, 2024, 32 : 35 - 35
  • [9] GL0034 (Utreglutide), a novel, long acting, glucagon-like peptide 1 receptor agonist (GLP-1 RA), results of a phase 1 study in healthy individuals
    Thennati, Rajamannar
    Burade, Vinod
    Natarajan, Muthukumaran
    Shahi, Pradeep
    Nagaraja, Ravishankara
    Panchal, Satish
    Agrawal, Sudeep
    Jandrain, Bernard
    Duvauchelle, Thierry
    Pratley, Richard E.
    Thorens, Bernard
    Vilsboll, Tina
    JOURNAL OF HEPATOLOGY, 2023, 78 : S607 - S608
  • [10] Once Weekly Utreglutide (GL0034), a Glucagon-like Peptide-1 Receptor Agonist, at 4 x 450 μg Doses Reduces Blood Pressure, Lipids, and Body Weight in Post-menopausal Females: A Phase I Study
    Thennati, Rajamannar
    Burade, Vinod
    Natarajan, Muthukumaran
    Shahi, Pradeep
    Nagaraja, Ravishankara
    Agrawal, Sudeep
    Duvauchelle, Thierry
    Pratley, Richard
    Thorens, Bernard
    Vilsboll, Tina
    CIRCULATION, 2024, 150
12345